Money
Filter News
Found 84,387 articles
-
To help support the launch of Lyfgenia, bluebird bio on Monday entered into a five-year term loan deal with Hercules Capital that will extend the biotech’s cash runway through the first quarter of 2026.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
CB Scientific, Inc. Concludes its Annual Meeting of Stockholders
3/19/2024
CB Scientific, Inc., a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced that the company successfully concluded its Annual Meeting of Stockholders on Thursday, March 14, 2024 as planned.
-
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/19/2024
Tourmaline Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and outlined recent business highlights.
-
LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements
3/19/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024.
-
Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform
3/19/2024
Aegis Life receives a program-related investment of $4.45M from the Bill & Melinda Gates Foundation.
-
ATCC Announces Award from the National Cancer Institute to Provide Biospecimen Processing Services and Assays for Cancer Research
3/19/2024
ATCC will continue to support the National Cancer Institute's (NCI) mission to prevent cancer and the Division of Cancer Epidemiology and Genetics (DCEG) Biospecimen Activity and Assay Support (BAAS) program.
-
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
3/19/2024
Enliven Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses.
-
Newron Presents 2023 Financial Results and Provides 2024 Outlook
3/19/2024
Newron Pharmaceuticals S.p.A. announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
-
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
3/19/2024
Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
-
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
3/19/2024
Fennec Pharmaceuticals Inc. announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024.
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
TCBP Announces Exercise of Series D Warrants For Cash
3/18/2024
TC BioPharm PLC announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares at an exercise price of $2.02.
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
3/18/2024
CytomX Therapeutics, Inc. today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX.
-
ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round
3/18/2024
ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
3/18/2024
Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
-
Madrigal Pharmaceuticals Announces Proposed Public Offering - March 18, 2024
3/18/2024
Madrigal Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock.
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
3/18/2024
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease, including those who are uninsured and underinsured.
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3/18/2024
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc.
-
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.